Key Points – Fresenius Medical Care reported solid Q2 results, with organic revenue up 5% and operating income up 23% at constant currency, supported by margin expansion and EUR 67 million in FME25+ savings.
The company reaffirmed its 2026 outlook for broadly flat revenue and elevated operating income. – U.S. treatment volumes remain a key weakness: same-market treatment growth fell 0.9% because of referral-conversion and operational issues, leading management to expect full-year U.S. growth to remain near Q2 levels
Corrective actions are expected to have a more meaningful impact in 2027. – Care Delivery earnings rose sharply, while Value-Based Care returned to profitability; however, Care Enablement earnings declined amid China-related pressures and higher costs. The company completed its initial EUR 1 billion buyback and launched a second EUR 1 billion repurchase program. – Hospital Stocks – Best Hospital Stocks to Buy Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) reported second-quarter 2026 organic revenue growth of 5% and a 23% increase in operating income at constant currency, while confirming its full-year outlook despite weaker U.S. treatment volumes and anticipated reimbursement-related headwinds in the second half.
Chief Executive Officer Helen Giza said the company’s operating-income growth accelerated in line with its planned 2026 phasing, supported by organic revenue development, margin expansion and savings from its FME25+ transformation program. The program generated EUR 67 million of sustainable savings during the quarter, she said. – Best Healthcare Stocks – Healthcare Stocks to Buy Now The company also completed its initial EUR 1 billion share repurchase program ahead of schedule and began a second EUR 1 billion program. Net leverage stood at 2.6 times, near the lower end of Fresenius Medical Care’s target range of 2.5 to 3 times.